- Maximizing profit by creating, leveraging products with 10-to-20x profitability margins
- Investors encouraged to review CBD Biotech’s impressive product line, strategic plan for revenue increase.
- Driving growth in new year with growing demand for CBD products
ChineseInvestors.com Inc. (OTCQB: CIIX) is a leading financial-information website for Chinese-speaking investors in the United States and China. CIIX CEO Warren Wang recently discussed the company’s goals and bright outlook for 2020 during a MoneyTV.net interview with Donald Baillargeon (http://ibn.fm/PlWY7).
The new year looks promising for CIIX, Wang stated. Using Chinese language character sets, the company offers investor-education products and services, real-time market commentary, analysis and educational-related services as well as advertising, public-relations-related support services and consultative services to smaller private companies.
In addition to financial services, the company has invested in the growing demand for cannabidiol (CBD)-based nutrition and health products. An IPO of CIIX’s wholly owned foreign enterprise, CBD Biotech, is anticipated early this year (http://ibn.fm/q0Ycx). In his interview, Wang gave an overview of CBD Biotech’s impressive product line, and he urged investors to do likewise in order to grasp the company’s plan to achieve profitability.
CBD Biotech’s major asset is its 40,000 repeat customers, said Wang, who discussed a B2C division of the company whose purpose is to target these consumers through telemarking and social media. The goal is to see how to retain this targeted group and keep these customers coming back. In addition, a separate CBD Biotech B2B division is working to maximize revenue to wholesalers. The two divisions have the same goals: increase sales, lower costs and maximize profitability.
Regarding stock price, Wang pointed out the hard work of employees, the company’s revenue, and the quality of the product line and profit margins as he shared with investors his confidence in the future of CIIX. CBD cosmetics products have a 10-to-20x profit margin, Wang noted, as he explained that the CBD cosmetic product line will be a vital part of driving growth as the company works to lower costs and maximize profitability. The company achieved almost $5 million in revenue during calendar year 2019, Wang said, and he expressed his optimism regarding the upcoming year as well.
In an earlier interview with Baillargeon (http://ibn.fm/iAVOP), Wang emphasized the bright future of the hemp/CBD industry in China, which has four times the market potential of America. CBD Biotech is one of the first companies to enter the industry, solidifying its place as a big player in the future of cannabis in China.
Last year was a successful year for CIIX, and Wang is looking forward to continued profitability and successful in 2020 as the company works toward an even more stable future.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.